RBC Capital Maintains Outperform on QuidelOrtho, Lowers Price Target to $81
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Conor McNamara maintains an Outperform rating on QuidelOrtho (NASDAQ:QDEL) but lowers the price target from $130 to $81.

February 14, 2024 | 3:41 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
RBC Capital maintains an Outperform rating on QuidelOrtho but lowers the price target from $130 to $81.
The reduction in the price target from $130 to $81 by a reputable analyst firm like RBC Capital could lead to a negative short-term impact on QuidelOrtho's stock price. Investors often view such adjustments as a signal of potential concerns about the company's future performance, even though the Outperform rating was maintained. This could result in decreased investor confidence and a possible decline in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100